MCID: EXT027
MIFTS: 32

Extrahepatic Bile Duct Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Extrahepatic Bile Duct Adenocarcinoma

MalaCards integrated aliases for Extrahepatic Bile Duct Adenocarcinoma:

Name: Extrahepatic Bile Duct Adenocarcinoma 12 15
Adenocarcinoma of the Extrahepatic Bile Duct 12 70
Adenocarcinoma of Extrahepatic Bile Duct 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3495
NCIt 50 C7975
UMLS 70 C0279659

Summaries for Extrahepatic Bile Duct Adenocarcinoma

Disease Ontology : 12 An extrahepatic bile duct carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Extrahepatic Bile Duct Adenocarcinoma, also known as adenocarcinoma of the extrahepatic bile duct, is related to papillary extrahepatic bile duct adenocarcinoma and bile duct adenocarcinoma, and has symptoms including vomiting, abdominal pain and pruritus. An important gene associated with Extrahepatic Bile Duct Adenocarcinoma is SLC7A5 (Solute Carrier Family 7 Member 5), and among its related pathways/superpathways are Cell surface interactions at the vascular wall and Amino acid transport across the plasma membrane. The drugs Oxaliplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and lymph node.

Related Diseases for Extrahepatic Bile Duct Adenocarcinoma

Graphical network of the top 20 diseases related to Extrahepatic Bile Duct Adenocarcinoma:



Diseases related to Extrahepatic Bile Duct Adenocarcinoma

Symptoms & Phenotypes for Extrahepatic Bile Duct Adenocarcinoma

UMLS symptoms related to Extrahepatic Bile Duct Adenocarcinoma:


vomiting; abdominal pain; pruritus; nausea; icterus; malaise

Drugs & Therapeutics for Extrahepatic Bile Duct Adenocarcinoma

Drugs for Extrahepatic Bile Duct Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
2
Gemcitabine Approved Phase 3 95058-81-4 60750
3
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
4 Immunosuppressive Agents Phase 3
5 Immunologic Factors Phase 3
6 Anti-Infective Agents Phase 3
7 Liver Extracts Phase 3
8 Antiviral Agents Phase 3
9 Antimetabolites Phase 3
10
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
11
Fluorouracil Approved Phase 2 51-21-8 3385
12
leucovorin Approved Phase 2 58-05-9 6006
13
Melphalan Approved Phase 2 148-82-3 4053 460612
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Pancrelipase Approved, Investigational Phase 2 53608-75-6
16
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
17
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
18
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
20 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
21
Molgramostim Investigational Phase 2 99283-10-0
22 Antidotes Phase 2
23 Micronutrients Phase 2
24 Trace Elements Phase 2
25 Vitamin B9 Phase 2
26 Nutrients Phase 2
27 Vitamin B Complex Phase 2
28 Hormones Phase 2
29 Folate Phase 2
30 Vitamins Phase 2
31 Protective Agents Phase 2
32 Calcium, Dietary Phase 2
33
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
34 Protein Kinase Inhibitors Phase 2
35 Alkylating Agents Phase 2
36 pancreatin Phase 2
37 Cola Phase 2
38 Adjuvants, Immunologic Phase 2
39 Vaccines Phase 2
40 Freund's Adjuvant Phase 2
41 Antineoplastic Agents, Immunological Phase 2
42
Calcium Nutraceutical Phase 2 7440-70-2 271
43
Durvalumab Approved, Investigational Phase 1 1428935-60-7
44
Guadecitabine Investigational Phase 1 929901-49-5
45 Immunoglobulins Phase 1
46 Antibodies Phase 1
47 Immunoglobulins, Intravenous Phase 1
48 Antibodies, Monoclonal Phase 1

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
2 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
3 Study Of Gemcitabine, Leukovorin, And Fluorouracil Used To Treat Locally Advanced And Metastatic Pancreatic And Biliary Adenocarcinomas Unknown status NCT00010088 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
4 Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
5 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
6 A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
7 Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
8 Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
9 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
10 A Phase II Study Trastuzumab (NSC 688097) in Her2/Neu Positive Cancer of the Gallbladder or Biliary Tract (NCI 7756) Terminated NCT00478140 Phase 2
11 Phase II and Pharmacodynamic Study of PS-341 in Patients With Unresectable or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Terminated NCT00085410 Phase 2 bortezomib
12 Pilot Study of Gemcitabine and IORT/EBRT in Locally Advanced Upper Gastrointestinal Malignancies Completed NCT00544193 Phase 1 gemcitabine hydrochloride
13 Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer. Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
14 Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies Completed NCT00073944 Phase 1 forodesine hydrochloride
15 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
16 A Two-Part Phase I Study of the Addition of Oxaliplatin to Gemcitabine, and Then Erlotinib Plus Oxaliplatin to Gemcitabine as Radiosensitizers for Pancreatic and Biliary Adenocarcinoma Completed NCT00266097 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin;gemcitabine hydrochloride;Oxaliplatin
17 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
18 A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer Recruiting NCT03257761 Phase 1 Guadecitabine

Search NIH Clinical Center for Extrahepatic Bile Duct Adenocarcinoma

Genetic Tests for Extrahepatic Bile Duct Adenocarcinoma

Anatomical Context for Extrahepatic Bile Duct Adenocarcinoma

MalaCards organs/tissues related to Extrahepatic Bile Duct Adenocarcinoma:

40
Liver, T Cells, Lymph Node

Publications for Extrahepatic Bile Duct Adenocarcinoma

Articles related to Extrahepatic Bile Duct Adenocarcinoma:

(show all 20)
# Title Authors PMID Year
1
Hepatoid Adenocarcinoma of the Extrahepatic Bile Duct in a Patient with Polysplenia Syndrome. 61
28202861 2017
2
Differentiation grade for extrahepatic bile duct adenocarcinoma: Assessed by diffusion-weighted imaging at 3.0-T MR. 61
27776649 2016
3
Synchronous double primary squamous cell carcinoma and adenocarcinoma of the extrahepatic bile duct: a case report. 61
25986701 2015
4
The utility of villin and mammaglobin in the differential diagnosis between intrahepatic cholangiocarcinoma and breast cancer. 61
25153498 2015
5
Pathologic observations of the duodenum in 615 consecutive duodenal specimens in a single Japanese hospital: II. malignant lesions. 61
22295147 2012
6
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. 61
20224368 2010
7
Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: case report and review of the literature. 61
20003448 2009
8
Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient's prognosis and recurrent status of extrahepatic bile duct carcinoma. 61
19420730 2009
9
Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients. 61
19158445 2009
10
Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. 61
18754070 2008
11
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. 61
17148994 2006
12
Papillary adenocarcinoma of the extrahepatic bile duct in a Holstein cow. 61
15657275 2005
13
A fatal overdose of the ergot derivative cabergoline. 61
15485721 2004
14
Image analysis of Transwell assays in the assessment of invasion by malignant cell lines. 61
12000178 2002
15
Comparison between pancreatoduodenectomy and hepatopancreatoduodenectomy for bile duct cancer. 61
11490856 2001
16
Sclerosing adenocarcinoma of the extrahepatic bile duct in a cat. 61
9133721 1997
17
Three-dimensional reconstruction of perineural invasion in carcinoma of the extrahepatic bile ducts. 61
8976871 1996
18
Carcinoma of the extrahepatic bile duct. 61
8256134 1993
19
[Radiotherapy for extrahepatic bile duct cancer--an analysis of 12 cases]. 61
2125921 1990
20
Adenocarcinoma of the extrahepatic bile duct in a cat. 61
979176 1976

Variations for Extrahepatic Bile Duct Adenocarcinoma

Expression for Extrahepatic Bile Duct Adenocarcinoma

Search GEO for disease gene expression data for Extrahepatic Bile Duct Adenocarcinoma.

Pathways for Extrahepatic Bile Duct Adenocarcinoma

Pathways related to Extrahepatic Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.41 SLC7A8 SLC7A5
2
Show member pathways
10.47 SLC7A8 SLC7A5
3 10.04 SLC7A8 SLC7A5

GO Terms for Extrahepatic Bile Duct Adenocarcinoma

Cellular components related to Extrahepatic Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basolateral plasma membrane GO:0016323 9.16 SLC7A8 SLC7A5
2 basal plasma membrane GO:0009925 8.96 SLC7A8 SLC7A5
3 microvillus membrane GO:0031528 8.62 SLC7A8 SLC7A5

Biological processes related to Extrahepatic Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.63 SLC7A8 SLC7A5 SLC1A7
2 leukocyte migration GO:0050900 9.48 SLC7A8 SLC7A5
3 amino acid transport GO:0006865 9.43 SLC7A8 SLC7A5
4 amino acid transmembrane transport GO:0003333 9.4 SLC7A8 SLC7A5
5 L-amino acid transport GO:0015807 9.37 SLC7A8 SLC7A5
6 neutral amino acid transport GO:0015804 9.32 SLC7A8 SLC7A5
7 amino acid import across plasma membrane GO:0089718 9.26 SLC7A8 SLC7A5
8 thyroid hormone transport GO:0070327 9.16 SLC7A8 SLC7A5
9 L-leucine import across plasma membrane GO:1903801 8.96 SLC7A8 SLC7A5
10 leucine import across plasma membrane GO:0098713 8.62 SLC7A8 SLC7A5

Molecular functions related to Extrahepatic Bile Duct Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transporter activity GO:0022857 9.4 SLC7A8 SLC7A5
2 amino acid transmembrane transporter activity GO:0015171 9.37 SLC7A8 SLC7A5
3 peptide antigen binding GO:0042605 9.32 SLC7A8 SLC7A5
4 L-amino acid transmembrane transporter activity GO:0015179 9.26 SLC7A8 SLC7A5
5 neutral amino acid transmembrane transporter activity GO:0015175 9.16 SLC7A8 SLC7A5
6 thyroid hormone transmembrane transporter activity GO:0015349 8.96 SLC7A8 SLC7A5
7 L-leucine transmembrane transporter activity GO:0015190 8.62 SLC7A8 SLC7A5

Sources for Extrahepatic Bile Duct Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....